Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
NCT04649021Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Dec 2020
- Primary completion
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BNT162b2 18-85 years of age with Placebo 18-85 years of age (2 arms). Primary endpoints: Seroconversion Rate of SARS-CoV-2 Serum Neutralizing Titers and Geometric Mean Titer of SARS-CoV-2 Serum Neutralizing Titers. Started Dec 2020; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04649021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649021.